Department of Gastroenterology and Hepatology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan.
Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.
PLoS One. 2022 Mar 11;17(3):e0265172. doi: 10.1371/journal.pone.0265172. eCollection 2022.
The upregulation of PODXL and ITGB1 in surgically resected pancreatic cancer tissues is correlated with an unfavorable postoperative prognosis. The aim of this study was to investigate whether PODXL and ITGB1 are useful preoperative markers for the prognosis of postoperative pancreatic cancer patients in comparison with the TNM staging system. Immunohistochemistry was performed using anti-PODXL and anti-ITGB1 antibodies on 24 pancreatic cancer tissue samples preoperatively obtained by endoscopic ultrasound-guided fine-needle aspiration biopsy. Cox proportional hazards regression analysis was performed to investigate if the UICC TNM stage and upregulation of PODXL and ITGB1 were correlated with postoperative overall survival rates. Univariate analysis revealed that PODXL, TNM stage, lymphatic invasion and the combination of PODXL with ITGB1 are correlated with postoperative survival. Multivariate analysis demonstrated TNM stage and the combination of PODXL with ITGB1 to be correlated with postoperative survival, and the combination of PODXL with ITGB1 most accurately predicted the postoperative outcomes of pancreatic cancer patients before resection. Therefore, upregulation of PODXL and ITGB1 may indicate preoperative neoadjuvant therapy for pancreatic cancer patients by accurately predicting the postoperative prognosis.
在手术切除的胰腺癌组织中，PODXL 和 ITGB1 的上调与术后不良预后相关。本研究旨在探讨与 TNM 分期系统相比，PODXL 和 ITGB1 是否可作为预测术后胰腺癌患者预后的有用术前标志物。通过内镜超声引导下细针抽吸活检术术前获得的 24 例胰腺癌组织样本，用抗 PODXL 和抗 ITGB1 抗体进行免疫组织化学染色。采用 Cox 比例风险回归分析，探讨 UICC TNM 分期和 PODXL、ITGB1 的上调与术后总生存率的相关性。单因素分析显示，PODXL、TNM 分期、淋巴浸润以及 PODXL 与 ITGB1 的联合与术后生存相关。多因素分析表明，TNM 分期和 PODXL 与 ITGB1 的联合与术后生存相关，并且 PODXL 与 ITGB1 的联合最能准确预测术前胰腺癌患者的术后结局。因此，PODXL 和 ITGB1 的上调可能提示术前对胰腺癌患者进行新辅助治疗，从而准确预测术后预后。
